The Clinicopathological and Prognostic Impact of 14-3-3 Protein Isoforms Expression in Human Cholangiocarcinoma by Immunohistochemistry |
Wu, Qiao
(Department of General Surgery, Peking Union Medical College Hospital)
Liu, Chang-Zheng (Department of Biochemistry, National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College) Tao, Lian-Yuan (Department of General Surgery, Peking Union Medical College Hospital) Yu, Lan (Department of General Surgery, Peking Union Medical College Hospital) Liu, Wei (Department of General Surgery, Peking Union Medical College Hospital) Chen, Song-Sen (Department of Biochemistry, National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College) He, Xiao-Dong (Department of General Surgery, Peking Union Medical College Hospital) |
1 | Fava G (2010). Molecular mechanisms of cholangiocarcinoma. World J Gastrointest Pathophysiol, 1, 12-22. DOI |
2 | Guweidhi A, Kleeff J, Giese N, et al (2004). Enhanced expression of 14-3-3sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis. Carcinogenesis, 25, 1575-85. DOI |
3 | Iwata N, Yamamoto H, Sasaki S, et al (2000). Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene, 19, 5298-302. DOI ScienceOn |
4 | Jeanteur P (2000). [14-3-3sigma (stratifin), a potential tumor suppressor frequently inactivated by methylation in cancer of the breast]. Bull Cancer, 87, 525. |
5 | Keshamouni VG, Michailidis G, Grasso CS, et al (2006). Differential protein expression profiling by iTRAQ- 2DLC-MS/MS of lung cancer cells undergoing epithelialmesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res, 5, 1143-54. DOI ScienceOn |
6 | Kilani RT, Maksymowych WP, Aitken A, et al (2007). Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol, 34, 1650-7. |
7 | Lee EK, Lee YS, Lee H, Choi CY, Park SH (2009). 14-3-3epsilon protein increases matrix metalloproteinase-2 gene expression via p38 MAPK signaling in NIH3T3 fibroblast cells. Exp Mol Med, 41, 453-561. DOI ScienceOn |
8 | Liang S, Xu Y, Shen G, et al (2009). Quantitative protein expression profiling of 14-3-3 isoforms in human renal carcinoma shows 14-3-3 epsilon is involved in limitedly increasing renal cell proliferation. Electrophoresis, 30, 4152-62. DOI |
9 | Lim JH (2003). Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. AJR Am J Roentgenol, 181, 819-27. DOI ScienceOn |
10 | Martin D, Brown-Luedi M, Chiquet-Ehrismann R (2003). Tenascin-C signaling through induction of 14-3-3 tau. J Cell Biol, 160, 171-5. DOI ScienceOn |
11 | Miyakawa S, Ishihara S, Horiguchi A, et al (2009). Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from, 1998 to, 2004 in Japan. J Hepatobiliary Pancreat Surg, 16, 1-7. DOI |
12 | Mosconi S, Beretta GD, Labianca R, et al (2009). Cholangiocarcinoma. Crit Rev Oncol Hematol, 69, 259-70. DOI |
13 | Nomura M, Shimizu S, Sugiyama T, et al (2003). 14-3-3 Interacts directly with and negatively regulates pro-apoptotic Bax. J Biol Chem, 278, 2058-65. DOI ScienceOn |
14 | Patel T (2001). Increasing incidence and mortality of primary intrahepatic cholangiocarcinomain the United States. Hepatology, 33, 1353-7. DOI ScienceOn |
15 | Porter GW, Khuri FR, Fu H (2006). Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Seminars Cancer Biol, 16, 193-202. DOI ScienceOn |
16 | Samuel T, Weber HO, Rauch P, et al (2001). The G2/M regulator 14-3-3sigma prevents apoptosis through sequestration of Bax. J Biol Chem, 276, 45201-6. DOI ScienceOn |
17 | Shankardas J, Senchyna M, Dimitrijevich SD (2008). Presence and distribution of 14-3-3 proteins in human ocular surface tissues. Mol Vis, 14, 2604-15. |
18 | Sugiyama A, Miyagi Y, Komiya Y, et al (2003). Forced expression of antisense 14-3-3beta RNA suppresses tumor cell growth in vitro and in vivo. Carcinogenesis, 24, 1549-59. DOI |
19 | Shu Y, Wang B, Wang J, Wang JM, Zou SQ (2011). Identification of methylation profile of HOX genes in extrahepatic cholangiocarcinoma. World J Gastroenterol, 17, 3407-19. DOI |
20 | Sinha P, Hutter G, Kottgen E, et al (1999). Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis, 20, 2952-60. DOI ScienceOn |
21 | Suzuki H, Itoh F, Toyota M, et al (2000). Inactivation of the 14-3-3 sigma gene is associated with 5' CpG island hypermethylation in human cancers. Cancer Res, 60, 4353-7. |
22 | Tio TL, Cheng J, Wijers OB, Sars PR, Tytgat GN (1991). Endosonographic TNM staging of extrahepatic bile duct cancer: comparison with pathological staging. Gastroenterology, 100, 1351-61. |
23 | Todd A, Cossons N, Aitken A, Price GB, Zannis-Hadjopoulos M (1998). Human cruciform binding protein belongs to the 14-3-3 family. Biochemistry, 37, 14317-25. DOI |
24 | Tompkins RK, Thomas D, Wile A, Longmire WP Jr (1981). Prognostic factors in bile duct carcinoma: analysis of 96 cases. Ann Surg, 194, 447-57. DOI ScienceOn |
25 | Toshima JY, Toshima J, Watanabe T, Mizuno K (2001). Binding of 14-3-3 beta regulates the kinase activity and subcellular localization of testicular protein kinase 1. J Biol Chem, 276, 43471-81. DOI |
26 | Tzivion G, Gupta VS, Kaplun L, Balan V (2006). 14-3-3 proteins as potential oncogenes. Seminars in cancer biology. Semin Cancer Biol, 16, 203-13. DOI ScienceOn |
27 |
Zang D, Li X, Zhang L (2010). 14-3-3 |
28 | Wang Y, Jacobs C, Hook KE, et al (2000). Binding of 14-3-3 beta to the carboxyl terminus of Wee1 increases Wee1 stability, kinase activity, and G2-M cell population. Cell Growth Differ, 11, 211-9. |
29 | Wijaya I, Abdullah M (2011). Diagnosis and treatment update: cholangiocarcinoma. Acta Med Indones, 43, 212-5. |
30 | Wilker E, Yaffe MB (2004). 14-3-3 Proteins--a focus on cancer and human disease. J Mol Cell Cardiol, 37, 633-42. DOI ScienceOn |
31 | Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ (1996). Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell, 87, 619-28. DOI ScienceOn |
32 | Zhai J, Lin H, Shamim M, Schlaepfer WW, Canete-Soler R (2001). Identification of a novel interaction of 14-3-3 with p190RhoGEF. J Biol Chem, 276, 41318-24. DOI |
![]() |